SecBot SecBot

Maintaining Investments in New Innovation Act

H.R. 5547 Rep. Wiley Nickel (D-NC-13) In committee
Bill text PDF
  1. Introduced Sep 18
  2. Committee Sep 18
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Sep 18, 2023Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
6companies, 21 filings
Subscribe to see spend
Member trades
7trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

6 companies
Companies by sector
Biotech & Pharma 6
Search all 6 companies, their asks and price moves Subscribe

Summary

Maintaining Investments in New Innovation Act

Full summary1 paragraphs

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Library of Congress summary, Sep 18, 2023

Summary versions
  • Introduced in HouseSep 18, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.